Gerard London

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/12192539/publications.pdf

Version: 2024-02-01

44 papers

2,565 citations

304602 22 h-index 47 g-index

48 all docs 48 docs citations

48 times ranked

3526 citing authors

#	Article	IF	CITATIONS
1	Kidney Disease: Improving Global Outcomes guidelines on anaemia management in chronic kidney disease: a European Renal Best Practice position statement. Nephrology Dialysis Transplantation, 2013, 28, 1346-1359.	0.4	628
2	The systemic nature of CKD. Nature Reviews Nephrology, 2017, 13, 344-358.	4.1	265
3	Interaction Between Hypertension and Arterial Stiffness. Hypertension, 2018, 72, 796-805.	1.3	189
4	Improvement of mineral and bone metabolism markers is associated with better survival in haemodialysis patients: the COSMOS study. Nephrology Dialysis Transplantation, 2015, 30, 1542-1551.	0.4	140
5	Use of phosphate-binding agents is associated with a lower risk of mortality. Kidney International, 2013, 84, 998-1008.	2.6	136
6	Pulmonary Hypertension in CKD. American Journal of Kidney Diseases, 2013, 61, 612-622.	2.1	119
7	Ambulatory Pulse Wave Velocity Is a Stronger Predictor of Cardiovascular Events and All-Cause Mortality Than Office and Ambulatory Blood Pressure in Hemodialysis Patients. Hypertension, 2017, 70, 148-157.	1.3	96
8	Hypertension in Chronic Kidney Disease Part 2. Hypertension, 2016, 67, 1102-1110.	1.3	86
9	COSMOS: the dialysis scenario of CKD–MBD in Europe. Nephrology Dialysis Transplantation, 2013, 28, 1922-1935.	0.4	79
10	A European Renal Best Practice (ERBP) position statement on the Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for the Management of Blood Pressure in Non-dialysis-dependent Chronic Kidney Disease: an endorsement with some caveats for real-life application. Nephrology Dialysis Transplantation, 2014, 29, 490-496.	0.4	76
11	The effect of dry-weight reduction guided by lung ultrasound on ambulatory blood pressure in hemodialysis patients: a randomized controlled trial. Kidney International, 2019, 95, 1505-1513.	2.6	65
12	SPARTE Study: Normalization of Arterial Stiffness and Cardiovascular Events in Patients With Hypertension at Medium to Very High Risk. Hypertension, 2021, 78, 983-995.	1.3	65
13	Hypertension in Chronic Kidney Disease Part 1. Hypertension, 2016, 67, 1093-1101.	1.3	63
14	Increased bone aluminum deposition after subtotal parathyroidectomy in dialyzed patients. Kidney International, 1985, 27, 785-791.	2.6	57
15	Con: Vascular calcification is a surrogate marker, but not the cause of ongoing vascular disease, and it is not a treatment target in chronic kidney disease. Nephrology Dialysis Transplantation, 2015, 30, 352-357.	0.4	52
16	Influence of Body Mass Index on the Association of Weight Changes with Mortality in Hemodialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 1725-1733.	2.2	49
17	Mineral and bone disease pattern in elderly haemodialysis patients. Nephrology Dialysis Transplantation, 2010, 25, 3062-3070.	0.4	37
18	Pulse Wave Velocity and Prognosis in End-Stage Kidney Disease. Hypertension, 2018, 71, 1126-1132.	1.3	28

#	Article	IF	Citations
19	The complexity of the cardio–renal link: taxonomy, syndromes, and diseases. Kidney International Supplements, 2011, 1, 2-5.	4.6	24
20	Validity of Vascular Calcification as a Screening Tool and as a Surrogate End Point in Clinical Research. Hypertension, 2015, 66, 3-9.	1.3	23
21	Serum phosphate optimal timing and range associated with patients survival in haemodialysis: the COSMOS study. Nephrology Dialysis Transplantation, 2019, 34, 673-681.	0.4	23
22	Prevalence and control of hypertension by 48-h ambulatory blood pressure monitoring in haemodialysis patients: a study by the European Cardiovascular and Renal Medicine (EURECA-m) working group of the ERA-EDTA. Nephrology Dialysis Transplantation, 2019, 34, 1542-1548.	0.4	21
23	Blood pressure monitoring in kidney transplantation: a systematic review on hypertension and target organ damage. Nephrology Dialysis Transplantation, 2021, 36, 1326-1346.	0.4	18
24	Deferoxamine Test and Bone Disease in Dialysis Patients With Mild Aluminum Accumulation. American Journal of Kidney Diseases, 1989, 14, 124-130.	2.1	17
25	Hypertension in kidney transplantation: a consensus statement of the †hypertension and the kidney' working group of the European Society of Hypertension. Journal of Hypertension, 2021, 39, 1513-1521.	0.3	16
26	Optimizing hypertension management in renal transplantation: a call to action. Nephrology Dialysis Transplantation, 2017, 32, 1959-1962.	0.4	14
27	Assessment of hypertension in kidney transplantation by ambulatory blood pressure monitoring: a systematic review and meta-analysis. CKJ: Clinical Kidney Journal, 2022, 15, 31-42.	1.4	14
28	Reappraisal in two European cohorts ofÂtheÂprognostic power of left ventricular massÂindexÂin chronic kidney failure. Kidney International, 2017, 91, 704-710.	2.6	13
29	Clinical imaging of vascular disease in chronic kidney disease. International Urology and Nephrology, 2016, 48, 827-837.	0.6	11
30	Relative prognostic impact of nutrition, anaemia, bone metabolism and cardiovascular comorbidities in elderly haemodialysis patients. Nephrology Dialysis Transplantation, 2019, 34, 848-858.	0.4	11
31	Weak within-individual association of blood pressure and pulse wave velocity in hemodialysis is related to adverse outcomes. Journal of Hypertension, 2019, 37, 2200-2208.	0.3	10
32	Prognostic values of left ventricular mass index in chronic kidney disease patients. Nephrology Dialysis Transplantation, 2021, 36, 665-672.	0.4	10
33	Protocol of the SPARTE Study: A Strategy for Preventing Cardiovascular and Renal Events based on ARTErial Stiffness. Artery Research, 2020, 26, 250-260.	0.3	10
34	A pharmacoepidemiological study of the multi-level determinants, predictors, and clinical outcomes of biosimilar epoetin alfa for renal anaemia in haemodialysis patients: background and methodology of the MONITOR-CKD5 study. Internal and Emergency Medicine, 2013, 8, 389-399.	1.0	9
35	Excess volume removal following lung ultrasound evaluation decreases central blood pressure and pulse wave velocity in hemodialysis patients: a LUST sub-study. Journal of Nephrology, 2020, 33, 1289-1300.	0.9	7
36	Long-term treatment with biosimilar epoetin- \hat{l}_{\pm} (HX575) in hemodialysis patients with renal anemia: real-world effectiveness and safety in the MONITOR-CKD5 study. Clinical Nephrology, 2018, 89, 1-9.	0.4	7

#	Article	IF	CITATIONS
37	ls blood pressure measured correctly in dialysis centres? Physicians' and patients' views. Nephrology Dialysis Transplantation, 2019, 34, 1612-1615.	0.4	6
38	Potential life-years gained over a 5-year period by correcting DOPPS-identified modifiable practices in haemodialysis: results from the European MONITOR-CKD5 study. BMC Nephrology, 2019, 20, 81.	0.8	6
39	Ambulatory blood pressure changes with lung ultrasound-guided dry-weight reduction in hypertensive hemodialysis patients: 12-month results of a randomized controlled trial. Journal of Hypertension, 2021, 39, 1444-1452.	0.3	4
40	Opponent's comments. Nephrology Dialysis Transplantation, 2015, 30, 351-352.	0.4	3
41	Risk-based individualisation of target haemoglobin in haemodialysis patients with renal anaemia in the post-TREAT era: theoretical attitudes versus actual practice patterns (MONITOR-CKD5 study). International Urology and Nephrology, 2015, 47, 837-845.	0.6	3
42	Risk of hospitalization associated with body mass index and weight changes among prevalent haemodialysis patients. Nefrologia, 2018, 38, 520-527.	0.2	3
43	Risk of hospitalization associated with body mass index and weight changes among prevalent haemodialysis patients. Nefrologia, 2018, 38, 520-527.	0.2	3
44	Survival with low- and high-flux dialysis. CKJ: Clinical Kidney Journal, 2021, 14, 1915-1923.	1.4	0